Pyxis Oncology, Inc. — Director's Dealing 2021

Oct 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2021-10-07

Reporting Person: Feingold Jay (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-07	Common Stock	A	43750	—	Acquired	43750	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-07	Stock Option (Right to buy)	$16	A	436929	Acquired	2031-10-07	Common Stock (436929)	Direct

Footnotes

F1: Represents shares of restricted stock that vest 25% of the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

F2: These stock options vest 25% on the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.